 | • レポートコード：GIR201115522 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、糸球体腎炎治療の世界市場を調査対象にし、糸球体腎炎治療の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002）、用途別分析（在宅ケア、クリニック、病院）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Achillion Pharmaceuticals Inc、Dimerix Bioscience Pty Ltd、Bristol-Myers Squibb Company、Anthera Pharmaceuticals Inc、Complexa Inc、Biogen Inc、Merck KGaA、ChemoCentryx Inc、Cellmid Ltd、GlaxoSmithKline Plc、Retrophin Inc、Visterra Inc、Omeros Corp、Rigel Pharmaceuticals Inc、Ra Pharmaceuticals Inc、Pfizer Inc、Takeda、Pharmalink AB ・企業別売上、市場シェア ・糸球体腎炎治療の地域別市場分析 ・糸球体腎炎治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・糸球体腎炎治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・糸球体腎炎治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・糸球体腎炎治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・糸球体腎炎治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・糸球体腎炎治療の種類別市場規模2015-2020：ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002 ・糸球体腎炎治療の用途別市場規模2015-2020：在宅ケア、クリニック、病院 ・糸球体腎炎治療の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論 |
Market Overview
The global Glomerulonephritis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Glomerulonephritis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Glomerulonephritis Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Glomerulonephritis Treatment market has been segmented into:
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
By Application, Glomerulonephritis Treatment has been segmented into:
Home Care
Clinic
Hospital
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Glomerulonephritis Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Glomerulonephritis Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Glomerulonephritis Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Glomerulonephritis Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Glomerulonephritis Treatment Market Share Analysis
Glomerulonephritis Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Glomerulonephritis Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Glomerulonephritis Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Glomerulonephritis Treatment are:
Achillion Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Bristol-Myers Squibb Company
Anthera Pharmaceuticals Inc
Complexa Inc
Biogen Inc
Merck KGaA
ChemoCentryx Inc
Cellmid Ltd
GlaxoSmithKline Plc
Retrophin Inc
Visterra Inc
Omeros Corp
Rigel Pharmaceuticals Inc
Ra Pharmaceuticals Inc
Pfizer Inc
Takeda
Pharmalink AB
Table of Contents
1 Glomerulonephritis Treatment Market Overview
1.1 Product Overview and Scope of Glomerulonephritis Treatment
1.2 Classification of Glomerulonephritis Treatment by Type
1.2.1 Global Glomerulonephritis Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Glomerulonephritis Treatment Revenue Market Share by Type in 2019
1.2.3 ACH-5228
1.2.4 AMY-101
1.2.5 Atacicept
1.2.6 Avacopan
1.2.7 AVX-002
1.3 Global Glomerulonephritis Treatment Market by Application
1.3.1 Overview: Global Glomerulonephritis Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Home Care
1.3.3 Clinic
1.3.4 Hospital
1.4 Global Glomerulonephritis Treatment Market by Regions
1.4.1 Global Glomerulonephritis Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Glomerulonephritis Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Glomerulonephritis Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Glomerulonephritis Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Glomerulonephritis Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Glomerulonephritis Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Glomerulonephritis Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Achillion Pharmaceuticals Inc
2.1.1 Achillion Pharmaceuticals Inc Details
2.1.2 Achillion Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Achillion Pharmaceuticals Inc SWOT Analysis
2.1.4 Achillion Pharmaceuticals Inc Product and Services
2.1.5 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Dimerix Bioscience Pty Ltd
2.2.1 Dimerix Bioscience Pty Ltd Details
2.2.2 Dimerix Bioscience Pty Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Dimerix Bioscience Pty Ltd SWOT Analysis
2.2.4 Dimerix Bioscience Pty Ltd Product and Services
2.2.5 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb Company
2.3.1 Bristol-Myers Squibb Company Details
2.3.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb Company SWOT Analysis
2.3.4 Bristol-Myers Squibb Company Product and Services
2.3.5 Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Anthera Pharmaceuticals Inc
2.4.1 Anthera Pharmaceuticals Inc Details
2.4.2 Anthera Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Anthera Pharmaceuticals Inc SWOT Analysis
2.4.4 Anthera Pharmaceuticals Inc Product and Services
2.4.5 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Complexa Inc
2.5.1 Complexa Inc Details
2.5.2 Complexa Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Complexa Inc SWOT Analysis
2.5.4 Complexa Inc Product and Services
2.5.5 Complexa Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Biogen Inc
2.6.1 Biogen Inc Details
2.6.2 Biogen Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Biogen Inc SWOT Analysis
2.6.4 Biogen Inc Product and Services
2.6.5 Biogen Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Merck KGaA
2.7.1 Merck KGaA Details
2.7.2 Merck KGaA Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Merck KGaA SWOT Analysis
2.7.4 Merck KGaA Product and Services
2.7.5 Merck KGaA Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 ChemoCentryx Inc
2.8.1 ChemoCentryx Inc Details
2.8.2 ChemoCentryx Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 ChemoCentryx Inc SWOT Analysis
2.8.4 ChemoCentryx Inc Product and Services
2.8.5 ChemoCentryx Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Cellmid Ltd
2.9.1 Cellmid Ltd Details
2.9.2 Cellmid Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Cellmid Ltd SWOT Analysis
2.9.4 Cellmid Ltd Product and Services
2.9.5 Cellmid Ltd Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 GlaxoSmithKline Plc
2.10.1 GlaxoSmithKline Plc Details
2.10.2 GlaxoSmithKline Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 GlaxoSmithKline Plc SWOT Analysis
2.10.4 GlaxoSmithKline Plc Product and Services
2.10.5 GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.11 Retrophin Inc
2.11.1 Retrophin Inc Details
2.11.2 Retrophin Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Retrophin Inc SWOT Analysis
2.11.4 Retrophin Inc Product and Services
2.11.5 Retrophin Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.12 Visterra Inc
2.12.1 Visterra Inc Details
2.12.2 Visterra Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Visterra Inc SWOT Analysis
2.12.4 Visterra Inc Product and Services
2.12.5 Visterra Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.13 Omeros Corp
2.13.1 Omeros Corp Details
2.13.2 Omeros Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Omeros Corp SWOT Analysis
2.13.4 Omeros Corp Product and Services
2.13.5 Omeros Corp Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.14 Rigel Pharmaceuticals Inc
2.14.1 Rigel Pharmaceuticals Inc Details
2.14.2 Rigel Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Rigel Pharmaceuticals Inc SWOT Analysis
2.14.4 Rigel Pharmaceuticals Inc Product and Services
2.14.5 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.15 Ra Pharmaceuticals Inc
2.15.1 Ra Pharmaceuticals Inc Details
2.15.2 Ra Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Ra Pharmaceuticals Inc SWOT Analysis
2.15.4 Ra Pharmaceuticals Inc Product and Services
2.15.5 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.16 Pfizer Inc
2.16.1 Pfizer Inc Details
2.16.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Pfizer Inc SWOT Analysis
2.16.4 Pfizer Inc Product and Services
2.16.5 Pfizer Inc Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.17 Takeda
2.17.1 Takeda Details
2.17.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Takeda SWOT Analysis
2.17.4 Takeda Product and Services
2.17.5 Takeda Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.18 Pharmalink AB
2.18.1 Pharmalink AB Details
2.18.2 Pharmalink AB Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Pharmalink AB SWOT Analysis
2.18.4 Pharmalink AB Product and Services
2.18.3 Pharmalink AB Glomerulonephritis Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Glomerulonephritis Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Glomerulonephritis Treatment Players Market Share
3.2.2 Top 10 Glomerulonephritis Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Glomerulonephritis Treatment Revenue and Market Share by Regions
4.2 North America Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
5 North America Glomerulonephritis Treatment Revenue by Countries
5.1 North America Glomerulonephritis Treatment Revenue by Countries (2015-2020)
5.2 USA Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
6 Europe Glomerulonephritis Treatment Revenue by Countries
6.1 Europe Glomerulonephritis Treatment Revenue by Countries (2015-2020)
6.2 Germany Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
6.4 France Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Glomerulonephritis Treatment Revenue by Countries
7.1 Asia-Pacific Glomerulonephritis Treatment Revenue by Countries (2015-2020)
7.2 China Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
7.5 India Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
8 South America Glomerulonephritis Treatment Revenue by Countries
8.1 South America Glomerulonephritis Treatment Revenue by Countries (2015-2020)
8.2 Brazil Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Glomerulonephritis Treatment by Countries
9.1 Middle East & Africa Glomerulonephritis Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Glomerulonephritis Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Glomerulonephritis Treatment Market Forecast by Type (2019-2024)
10.3 ACH-5228 Revenue Growth Rate (2015-2025)
10.4 AMY-101 Revenue Growth Rate (2015-2025)
10.5 Atacicept Revenue Growth Rate (2015-2025)
10.6 Avacopan Revenue Growth Rate (2015-2025)
10.7 AVX-002 Revenue Growth Rate (2015-2025)
11 Global Glomerulonephritis Treatment Market Segment by Application
11.1 Global Glomerulonephritis Treatment Revenue Market Share by Application (2015-2020)
11.2 Glomerulonephritis Treatment Market Forecast by Application (2019-2024)
11.3 Home Care Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Hospital Revenue Growth (2015-2020)
12 Global Glomerulonephritis Treatment Market Size Forecast (2021-2025)
12.1 Global Glomerulonephritis Treatment Market Size Forecast (2021-2025)
12.2 Global Glomerulonephritis Treatment Market Forecast by Regions (2021-2025)
12.3 North America Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
12.6 South America Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Glomerulonephritis Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Glomerulonephritis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Glomerulonephritis Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Glomerulonephritis Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Achillion Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 6. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Major Business
Table 7. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Achillion Pharmaceuticals Inc SWOT Analysis
Table 9. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 10. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Dimerix Bioscience Pty Ltd Corporate Information, Location and Competitors
Table 12. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Major Business
Table 13. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Dimerix Bioscience Pty Ltd SWOT Analysis
Table 15. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product and Solutions
Table 16. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Bristol-Myers Squibb Company Corporate Information, Location and Competitors
Table 18. Bristol-Myers Squibb Company Glomerulonephritis Treatment Major Business
Table 19. Bristol-Myers Squibb Company Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Bristol-Myers Squibb Company SWOT Analysis
Table 21. Bristol-Myers Squibb Company Glomerulonephritis Treatment Product and Solutions
Table 22. Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Anthera Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 24. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Major Business
Table 25. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Anthera Pharmaceuticals Inc SWOT Analysis
Table 27. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 28. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Complexa Inc Corporate Information, Location and Competitors
Table 30. Complexa Inc Glomerulonephritis Treatment Major Business
Table 31. Complexa Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Complexa Inc SWOT Analysis
Table 33. Complexa Inc Glomerulonephritis Treatment Product and Solutions
Table 34. Complexa Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Biogen Inc Corporate Information, Location and Competitors
Table 36. Biogen Inc Glomerulonephritis Treatment Major Business
Table 37. Biogen Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Biogen Inc SWOT Analysis
Table 39. Biogen Inc Glomerulonephritis Treatment Product and Solutions
Table 40. Biogen Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Merck KGaA Corporate Information, Location and Competitors
Table 42. Merck KGaA Glomerulonephritis Treatment Major Business
Table 43. Merck KGaA Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Merck KGaA SWOT Analysis
Table 45. Merck KGaA Glomerulonephritis Treatment Product and Solutions
Table 46. Merck KGaA Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. ChemoCentryx Inc Corporate Information, Location and Competitors
Table 48. ChemoCentryx Inc Glomerulonephritis Treatment Major Business
Table 49. ChemoCentryx Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 50. ChemoCentryx Inc SWOT Analysis
Table 51. ChemoCentryx Inc Glomerulonephritis Treatment Product and Solutions
Table 52. ChemoCentryx Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Cellmid Ltd Corporate Information, Location and Competitors
Table 54. Cellmid Ltd Glomerulonephritis Treatment Major Business
Table 55. Cellmid Ltd Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Cellmid Ltd SWOT Analysis
Table 57. Cellmid Ltd Glomerulonephritis Treatment Product and Solutions
Table 58. Cellmid Ltd Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. GlaxoSmithKline Plc Corporate Information, Location and Competitors
Table 60. GlaxoSmithKline Plc Glomerulonephritis Treatment Major Business
Table 61. GlaxoSmithKline Plc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 62. GlaxoSmithKline Plc SWOT Analysis
Table 63. GlaxoSmithKline Plc Glomerulonephritis Treatment Product and Solutions
Table 64. GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Retrophin Inc Corporate Information, Location and Competitors
Table 66. Retrophin Inc Glomerulonephritis Treatment Major Business
Table 67. Retrophin Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 68. Retrophin Inc SWOT Analysis
Table 69. Retrophin Inc Glomerulonephritis Treatment Product and Solutions
Table 70. Retrophin Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Visterra Inc Corporate Information, Location and Competitors
Table 72. Visterra Inc Glomerulonephritis Treatment Major Business
Table 73. Visterra Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 74. Visterra Inc SWOT Analysis
Table 75. Visterra Inc Glomerulonephritis Treatment Product and Solutions
Table 76. Visterra Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Omeros Corp Corporate Information, Location and Competitors
Table 78. Omeros Corp Glomerulonephritis Treatment Major Business
Table 79. Omeros Corp Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 80. Omeros Corp SWOT Analysis
Table 81. Omeros Corp Glomerulonephritis Treatment Product and Solutions
Table 82. Omeros Corp Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Rigel Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 84. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Major Business
Table 85. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 86. Rigel Pharmaceuticals Inc SWOT Analysis
Table 87. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 88. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Ra Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 90. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Major Business
Table 91. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 92. Ra Pharmaceuticals Inc SWOT Analysis
Table 93. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product and Solutions
Table 94. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Pfizer Inc Corporate Information, Location and Competitors
Table 96. Pfizer Inc Glomerulonephritis Treatment Major Business
Table 97. Pfizer Inc Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 98. Pfizer Inc SWOT Analysis
Table 99. Pfizer Inc Glomerulonephritis Treatment Product and Solutions
Table 100. Pfizer Inc Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Takeda Corporate Information, Location and Competitors
Table 102. Takeda Glomerulonephritis Treatment Major Business
Table 103. Takeda Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 104. Takeda SWOT Analysis
Table 105. Takeda Glomerulonephritis Treatment Product and Solutions
Table 106. Takeda Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Pharmalink AB Glomerulonephritis Treatment Type and Application
Table 108. Pharmalink AB Glomerulonephritis Treatment Major Business
Table 109. Pharmalink AB Glomerulonephritis Treatment Total Revenue (USD Million) (2017-2018)
Table 110. Pharmalink AB SWOT Analysis
Table 111. Pharmalink AB Glomerulonephritis Treatment Product and Solutions
Table 112. Pharmalink AB Glomerulonephritis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Global Glomerulonephritis Treatment Revenue (Million USD) by Players (2015-2020)
Table 114. Global Glomerulonephritis Treatment Revenue Share by Players (2015-2020)
Table 115. Global Glomerulonephritis Treatment Revenue (Million USD) by Regions (2015-2020)
Table 116. Global Glomerulonephritis Treatment Revenue Market Share by Regions (2015-2020)
Table 117. North America Glomerulonephritis Treatment Revenue by Countries (2015-2020)
Table 118. North America Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Table 119. Europe Glomerulonephritis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 120. Asia-Pacific Glomerulonephritis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 121. South America Glomerulonephritis Treatment Revenue by Countries (2015-2020)
Table 122. South America Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Table 123. Middle East and Africa Glomerulonephritis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 124. Middle East and Africa Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Table 125. Global Glomerulonephritis Treatment Revenue (Million USD) by Type (2015-2020)
Table 126. Global Glomerulonephritis Treatment Revenue Share by Type (2015-2020)
Table 127. Global Glomerulonephritis Treatment Revenue Forecast by Type (2021-2025)
Table 128. Global Glomerulonephritis Treatment Revenue by Application (2015-2020)
Table 129. Global Glomerulonephritis Treatment Revenue Share by Application (2015-2020)
Table 130. Global Glomerulonephritis Treatment Revenue Forecast by Application (2021-2025)
Table 131. Global Glomerulonephritis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Glomerulonephritis Treatment Picture
Figure 2. Global Glomerulonephritis Treatment Revenue Market Share by Type in 2019
Figure 3. ACH-5228 Picture
Figure 4. AMY-101 Picture
Figure 5. Atacicept Picture
Figure 6. Avacopan Picture
Figure 7. AVX-002 Picture
Figure 8. Glomerulonephritis Treatment Revenue Market Share by Application in 2019
Figure 9. Home Care Picture
Figure 10. Clinic Picture
Figure 11. Hospital Picture
Figure 12. Global Glomerulonephritis Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Glomerulonephritis Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Glomerulonephritis Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Glomerulonephritis Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Glomerulonephritis Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Glomerulonephritis Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Glomerulonephritis Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Glomerulonephritis Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Glomerulonephritis Treatment Revenue Market Share by Countries in 2019
Figure 45. China Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Glomerulonephritis Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Glomerulonephritis Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Glomerulonephritis Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Glomerulonephritis Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Glomerulonephritis Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Glomerulonephritis Treatment Revenue Share by Type in 2019
Figure 62. Global Glomerulonephritis Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global ACH-5228 Revenue Growth Rate (2015-2020)
Figure 64. Global AMY-101 Revenue Growth Rate (2015-2020)
Figure 65. Global Atacicept Revenue Growth Rate (2015-2020)
Figure 66. Global Avacopan Revenue Growth Rate (2015-2020)
Figure 67. Global AVX-002 Revenue Growth Rate (2015-2020)
Figure 68. Global Glomerulonephritis Treatment Revenue Share by Application (2015-2020)
Figure 69. Global Glomerulonephritis Treatment Revenue Share by Application in 2019
Figure 70. Global Glomerulonephritis Treatment Market Share Forecast by Application (2021-2025)
Figure 71. Global Home Care Revenue Growth Rate (2015-2020)
Figure 72. Global Clinic Revenue Growth Rate (2015-2020)
Figure 73. Global Hospital Revenue Growth Rate (2015-2020)
Figure 74. Global Glomerulonephritis Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Glomerulonephritis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Glomerulonephritis Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Glomerulonephritis Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
軟骨無形成症治療の世界市場 2020年 Market Overview The global Achondroplasia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Achondroplasia Treat…- 不安障害及びうつ病治療の世界市場 2020年 Market Overview The Anxiety Disorder and Depression Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value…
- 酒さ治療の世界市場 2020年 Market Overview The global Rosacea Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 1721.7 million by 2025, from USD 1526 million in 2019. The Rosacea Treatment ma…
- 第IX因子欠乏症治療の世界市場 2020年 Market Overview The global Factor IX Deficiency Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Factor IX Defi…
- グロボイド細胞白質ジストロフィー治療の世界市場 2020年 Market Overview The global Globoid Cell Leukodystrophy Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Globoid…